Marfan Syndrome (Paediatric)

1. Clinical Overview

Summary

Marfan Syndrome (MFS) is the most common heritable disorder of connective tissue worldwide, with profound implications for paediatric care. Caused by pathogenic variants in the FBN1 gene encoding Fibrillin-1, this multisystem disorder primarily affects the skeletal, cardiovascular, and ocular systems. The condition follows an autosomal dominant inheritance pattern, though approximately 25% of cases arise from de novo mutations. [1,2]

The defining clinical challenge in Marfan syndrome is progressive aortic root dilatation leading to potentially fatal Type A aortic dissection. In the pre-treatment era, median survival was only 32 years, with 90% of deaths attributable to cardiovascular complications. Modern medical and surgical management has transformed this prognosis dramatically, with contemporary life expectancy approaching that of the general population when appropriate surveillance and intervention are implemented. [3,4]

Early diagnosis using the Revised Ghent Nosology (2010) is paramount, as it enables initiation of cardiovascular prophylaxis, surveillance protocols, and timely surgical intervention. The paediatric presentation is particularly variable, ranging from neonatal Marfan syndrome with severe valve regurgitation and heart failure, to subtle manifestations detected only through family screening. Recognition of this phenotypic spectrum is essential for optimal outcomes. [5,6]

Clinical Pearls

The "Thumb Sign" (Steinberg Sign): Ask the patient to fold their thumb across the palm and close their fingers over it to make a fist. The sign is positive if the entire distal phalanx of the thumb protrudes beyond the ulnar border of the hand. This indicates arachnodactyly. Sensitivity approximately 65%, specificity 85% for Marfan syndrome. [7]

The "Wrist Sign" (Walker-Murdoch Sign): Ask the patient to grip their opposite wrist with thumb and fifth finger. The sign is positive if these digits overlap by at least the width of a fingernail. Combined with the Thumb Sign (both positive = 3 points on Systemic Score), this substantially increases diagnostic probability. [7]

Ectopia Lentis Direction - Critical Differential: In Marfan syndrome, the lens typically dislocates SUPERIORLY and TEMPORALLY (upward and outward) due to zonular weakness. In Homocystinuria, the main biochemical differential, lens dislocation is INFERIORLY and NASALLY (downward and inward). This directional difference can be life-saving in differentiating these conditions. [8]

Z-Score Interpretation: Aortic root measurements MUST be corrected for body surface area (BSA) in children. A Z-score > 2 (i.e., > 2 standard deviations above the mean for age/BSA) is considered significant dilatation. Z-score > 3 represents severe dilatation requiring intensified surveillance. Raw measurements without Z-scores are clinically meaningless in paediatrics. [9,10]

The "TGF-beta Paradox": While classically considered a structural protein disorder, Marfan syndrome pathogenesis is now understood to be predominantly driven by dysregulated TGF-beta signalling. Defective fibrillin cannot sequester TGF-beta, leading to excessive signalling. This insight explains why anti-TGF-beta therapies (Losartan) may be beneficial and why some manifestations (aortic wall weakness) are paradoxically characterized by TGF-beta-driven matrix metalloproteinase activity rather than simple structural deficiency. [11,12]

---

2. Epidemiology

Demographics

Prevalence and Incidence:

• Global Prevalence: 1 in 5,000 individuals (0.02%), making Marfan syndrome the most common inherited aortopathy. [1,2]
• Incidence: Approximately 1 in 5,000-10,000 live births, with no significant geographic or ethnic variation.
• Equal Gender Distribution: Unlike many genetic disorders, MFS affects males and females equally. [13]

Genetic Characteristics:

• Inheritance Pattern: Autosomal Dominant with complete penetrance but highly variable expressivity.
• De Novo Mutations: 25-30% of cases have no family history and represent new mutations. [14]
• Paternal Age Effect: De novo mutations are strongly associated with advanced paternal age (> 35 years), with mutation rate increasing approximately 2% per year of paternal age. [15]
• Penetrance: 100% (all individuals carrying pathogenic FBN1 variants manifest the disease), but clinical severity varies enormously even within families sharing identical mutations.
• Expressivity: Highly variable - some patients have life-threatening cardiovascular manifestations in childhood, others have minimal features until adulthood. [16]

Age of Diagnosis:

• Neonatal Presentation: less than 5% of cases present in the neonatal period with severe manifestations (see Neonatal Marfan Syndrome below).
• Childhood: 30-40% diagnosed in childhood through family screening or detection of skeletal/ocular features.
• Adolescence/Young Adulthood: 40-50% diagnosed when growth acceleration unmasks skeletal features or when cardiovascular manifestations develop.
• Late Diagnosis: 10-15% not diagnosed until adulthood, often following cardiovascular event or during family screening after sentinel case. [17]

Special Populations

Neonatal Marfan Syndrome:

• A distinct, severe phenotype affecting less than 5% of cases, usually associated with mutations in exons 24-32 of FBN1.
• Presents with severe mitral and/or tricuspid regurgitation, heart failure, and death within the first year if untreated.
• Requires early surgical intervention (valve repair/replacement) with high perioperative mortality.
• Poor prognostic markers: presentation less than 1 month of age, severe TR > 3+, pulmonary hypertension. [18,19]

Pregnancy Considerations:

• Maternal Marfan syndrome increases risk of:
  • Aortic dissection (4-10% during pregnancy/postpartum, risk highest in 3rd trimester and first month postpartum)
  • Preterm delivery (28% vs 11% in general population)
  • Fetal growth restriction
• Risk stratification depends on pre-pregnancy aortic root diameter:
  • less than 40 mm: Low risk (~1% dissection)
  • 40-45 mm: Moderate risk (~5% dissection)

  • 45 mm: High risk (~10% dissection), pregnancy contraindicated

• Requires multidisciplinary care with monthly echocardiography, beta-blocker continuation, and planned delivery. [20,21]

---

3. Pathophysiology

Molecular Basis

The FBN1 Gene and Fibrillin-1:

• Located on chromosome 15q21.1, the FBN1 gene spans 235 kb with 65 exons.
• Encodes Fibrillin-1, a 350 kDa glycoprotein that is the principal component of extracellular microfibrils.
• Over 3,000 different pathogenic variants have been identified, with most being unique to individual families (private mutations).
• Mutation types include missense (60%), frameshift/nonsense (30%), and splice-site variants (10%).
• No clear genotype-phenotype correlation for most mutations, though some exon 24-32 mutations associate with neonatal Marfan syndrome. [22,23]

Microfibril Structure and Function: Fibrillin-1 assembles into microfibrils that:

1. Form the scaffold for elastic fiber formation - provide tissue elasticity in aorta, ligaments, zonules of lens
2. Sequester and regulate growth factors, particularly members of the TGF-beta superfamily
3. Provide structural support to connective tissue throughout the body
4. Regulate cell signaling through integrin binding and matrix interactions [24]

Dual Mechanism of Disease

Modern understanding recognizes TWO complementary pathogenic mechanisms:

1. Structural Mechanism (Original Hypothesis):

• Defective fibrillin → weak microfibrils → reduced tissue elasticity
• Explains:
  • Aortic wall weakness (deficient elastic lamellae)
  • Joint laxity (loose ligaments)
  • Ectopia lentis (weak zonules cannot hold lens in place)
  • Pneumothorax (subpleural blebs from weak alveolar walls)
  • Dural ectasia (weak dural sac) [25]

2. Signaling Mechanism (Contemporary Understanding):

• Defective fibrillin cannot sequester TGF-beta → excessive TGF-beta signaling
• This paradigm shift has revolutionized understanding of pathophysiology:
  • "Excessive TGF-beta drives:"
    • Smooth muscle cell apoptosis in aortic media
    • Matrix metalloproteinase (MMP) upregulation → elastin degradation
    • Myxomatous valve degeneration
    • Abnormal bone growth and overgrowth phenotype
    • Lung parenchymal abnormalities [11,12,26]

Evidence for TGF-beta Hypothesis:

1. Elevated TGF-beta levels found in aortic tissue and serum of MFS patients
2. Mouse models show increased TGF-beta signaling precedes aortic pathology
3. TGF-beta neutralizing antibodies prevent aortic aneurysm in MFS mice
4. Angiotensin receptor blockers (ARBs), which inhibit TGF-beta signaling, show benefit in clinical trials
5. Some Loeys-Dietz syndrome mutations directly affect TGF-beta receptors yet produce Marfan-like phenotypes [27,28]

Tissue-Specific Manifestations

Cardiovascular System:

• Aortic Root Dilatation: Begins at sinuses of Valsalva, progresses proximally and distally

  • "Cystic medial necrosis: smooth muscle cell loss, elastic fiber fragmentation, proteoglycan accumulation"
  • "Progressive dilatation rate: 0.5-1.0 mm/year in children, accelerates during adolescent growth spurt"
  • Risk of dissection increases exponentially with diameter > 45mm [29,30]

• Mitral Valve Prolapse:

  • Myxomatous degeneration of valve leaflets (excess proteoglycans)
  • Elongated chordae tendineae → leaflet prolapse → regurgitation
  • Affects 60-80% of patients, usually mild-moderate
  • Can progress to severe MR requiring surgery [31]

Skeletal System:

• Overgrowth Phenotype: TGF-beta-driven increased linear bone growth

  • Tall stature (height > 95th percentile for family)
  • "Dolichostenomelia: disproportionately long limbs"
  • "Arachnodactyly: long, thin digits"
  • "Scoliosis (60% of patients): TGF-beta effects on vertebral growth plates [32]"

• Joint Laxity: Structurally weak ligaments permit hypermobility

  • Beighton score often ≥5/9
  • Risk of recurrent dislocations, chronic pain, early osteoarthritis [33]

Ocular System:

• Ectopia Lentis (50-80%): Zonular fibers composed primarily of fibrillin

  • Progressive stretching and rupture → lens subluxation
  • Usually bilateral and symmetric
  • "Direction: superotemporal (pathognomonic when present)"
  • Causes refractive errors, amblyopia if unilateral, retinal detachment risk [34]

• Myopia: Increased axial length of globe (30mm vs normal 24mm)

• Retinal Detachment: 5-11% lifetime risk (vs 0.06% general population)

Pulmonary System:

• Pneumothorax: 5-10% lifetime incidence, often recurrent
  • Apical blebs from weak alveolar walls
  • Can be first presentation in young adults
• Restrictive Lung Disease: Pectus deformity, scoliosis reduce lung volumes [35]

Dural System:

• Dural Ectasia (60-90%): Widening of dural sac in lumbosacral spine
  • Often asymptomatic
  • Can cause chronic low back pain, headaches, proximal leg weakness
  • "Detected on MRI: ballooning of dural sac, scalloping of vertebral bodies [36]"

---

4. Diagnostic Criteria (Revised Ghent Nosology 2010)

The Revised Ghent Nosology (2010) simplified diagnosis by emphasizing the cardinal manifestations: Aortic Root Dilatation and Ectopia Lentis, supported by FBN1 genetic testing. This replaced the earlier 1996 criteria that relied on extensive "feature counting" across systems. [5]

Key Principle

Diagnosis requires identification of the two cardinal features (Aorta and Lens), with genetic or systemic features providing supporting evidence. The presence of BOTH cardinal features is nearly pathognomonic for Marfan syndrome.

Diagnostic Algorithm

In ABSENCE of Family History:

In PRESENCE of Family History (1st-degree relative with confirmed MFS):

Systemic Score (Maximum 20 points; ≥7 = Positive)

Definitions of Cardinal Features

Aortic Root Dilatation (Ao):

• Z-score ≥2 at the sinuses of Valsalva
• Must be measured by echocardiography using leading-edge to leading-edge technique
• Z-score calculated using validated nomograms adjusting for age and BSA (e.g., Gautier, Campens, or Devereux equations) [9,10]
• Critical: Raw measurements are inadequate in children; Z-scores are mandatory

Ectopia Lentis (EL):

• Bilateral lens subluxation or dislocation
• Detected by slit-lamp examination after pupillary dilatation
• May be subtle; requires experienced ophthalmologist
• Direction: Typically superotemporal in Marfan syndrome [34]

FBN1 Mutation:

• Pathogenic or likely pathogenic variant identified through sequencing and deletion/duplication analysis
• Detection rate: 90-95% in patients meeting clinical criteria
• 5-10% of patients clinically diagnosed with MFS have no detectable FBN1 mutation (may have mutations in regulatory regions or alternate genes) [37]

Exclusion of Differential Diagnoses

Before diagnosing MFS, rule out:

• Loeys-Dietz Syndrome (TGFBR1/TGFBR2 mutations): Hypertelorism, bifid uvula/cleft palate, arterial tortuosity, aggressive aortic disease
• Ehlers-Danlos Syndrome, Vascular Type (COL3A1): Thin translucent skin, easy bruising, arterial/bowel rupture
• Homocystinuria (CBS deficiency): Intellectual disability, thromboembolism, downward lens dislocation, elevated urinary homocysteine
• MASS Phenotype: Myopia, Mitral prolapse, Aortic borderline (Zless than 2), Skin/Skeletal - does NOT meet criteria for MFS
• Shprintzen-Goldberg Syndrome: Craniosynostosis, intellectual disability, aortic root dilatation [38,39]

---

5. Clinical Presentation

The presentation of Marfan syndrome in children is highly variable, ranging from life-threatening neonatal manifestations to subtle findings detected only through family screening.

Age-Specific Presentations

Neonatal Period (less than 1 month):

• Severe Valve Regurgitation: Mitral and/or tricuspid regurgitation causing heart failure
  • Presents with tachypnea, poor feeding, failure to thrive, hepatomegaly
  • Requires urgent cardiology evaluation and often early surgical intervention
• Pulmonary Hypertension: Secondary to left-to-right shunting or lung hypoplasia
• Arachnodactyly and Dolichostenomelia: May be evident at birth
• Mortality: 40-90% in first year without surgical intervention [18,19]

Infancy (1-12 months):

• Failure to thrive (30-40% of cases)
• Hypotonia and motor delay (joint laxity)
• Persistent tachypnea (mitral regurgitation, pectus deformity)
• Recurrent respiratory infections

Childhood (1-10 years):

• Skeletal: Tall stature for family, arm span exceeds height, arachnodactyly, pectus deformity (excavatum or carinatum), scoliosis, pes planus
• Ocular: Myopia requiring strong correction, ectopia lentis (may cause monocular diplopia, glare)
• Cardiovascular: Usually asymptomatic; aortic dilatation detected on screening echo
• Identification Through Family Screening: Many children diagnosed when parent/sibling identified

Adolescence (10-18 years):

• Accelerated Growth: Pubertal growth spurt accentuates skeletal features
  • Height velocity may exceed 10 cm/year
  • Disproportionate limb lengthening becomes more obvious
• Worsening Scoliosis: Curve progression during growth spurt (Cobb angle > 20° in 60%)
• Cardiovascular Progression: Aortic dilatation accelerates (growth-related increased wall stress)
• Pneumothorax: First presentation in 5% of cases (typically males 15-30 years)
• Psychosocial Impact: Body image concerns, awareness of diagnosis and implications [40]

System-Based Clinical Features

Skeletal System (Present in 90-95%):

Major Features:

• Tall Stature: Height > 95th percentile for age/sex (but > 97th percentile for family background)
• Dolichostenomelia: Arm span to height ratio > 1.05
  • Measure arm span (fingertip to fingertip with arms outstretched)
  • Ratio > 1.05 in > 90% of MFS patients > 10 years
• Reduced Upper:Lower Segment Ratio: less than 0.86 (measure from pubis to floor for lower segment)
  • Reflects disproportionately long legs
• Arachnodactyly:
  • "Thumb Sign (Steinberg): Thumb protrudes beyond ulnar border when enclosed in fist (65% sensitivity)"
  • "Wrist Sign (Walker-Murdoch): Thumb and 5th finger overlap > 1 fingernail width when encircling opposite wrist (70% sensitivity)"
  • Metacarpal Index > 8.4 on hand X-ray (ratio of length to width of metacarpals 2-5) [7]

Other Features:

• Pectus Deformity (70%):
  • "Pectus Excavatum (sternum depressed inward): more common, can restrict cardiac function"
  • Pectus Carinatum (sternum protrudes outward): "pigeon chest"
  • Asymmetric chest wall (mixed deformity)
• Scoliosis (60%): Typically thoracolumbar, progresses during growth, Cobb angle > 40° requires surgery
• Spondylolisthesis: Anterior slippage of L5 on S1 (15% of patients)
• Protrusio Acetabuli (40%): Femoral head protrudes into pelvic cavity (seen on AP pelvis X-ray)
• Joint Hypermobility: Beighton score often ≥5/9, predisposes to chronic pain, dislocations
• Pes Planus (Flat Feet): Loss of medial longitudinal arch (75% of patients)
• High-Arched Palate: Narrow, V-shaped palate with dental crowding [32,33]

Ocular System (60-80%):

Cardinal Feature:

• Ectopia Lentis (50-80%):
  • Bilateral in > 95% of cases (unilateral should prompt consideration of trauma or alternate diagnosis)
  • Superotemporal displacement (60-70% of cases)
  • "Progressive: many not present at birth, develop during childhood/adolescence"
  • Detection requires slit-lamp examination after mydriasis by ophthalmologist
  • "Clinical signs suggesting ectopia lentis:"
    • Iridodonesis (iris tremulousness when eye moves)
    • Phacodonesis (lens tremulousness)
    • Visible edge of lens through undilated pupil
  • "Complications: Amblyopia (if monocular), refractive errors, glare, lens-induced glaucoma [34]"

Other Features:

• Severe Myopia: > 3 dioptres (60% of patients), due to increased axial length
• Flat Cornea: Reduced keratometry readings (less than 41 dioptres)
• Increased Axial Length: Globe length > 25mm (vs 23-24mm normal)
• Retinal Detachment: 5-11% lifetime risk, often associated with high myopia or lens dislocation
• Glaucoma: 10% of patients, may be secondary to lens displacement
• Blue Sclerae: Thinning allows visualization of underlying choroid (20% of patients)

Cardiovascular System (80-100%):

Cardinal Feature:

• Aortic Root Dilatation (75-100%):
  • Begins at sinuses of Valsalva, extends to ascending aorta
  • Usually detectable by late childhood/adolescence
  • "Progressive: expands at 0.5-1.0 mm/year (faster during growth spurts)"
  • Z-score > 2 = dilatation; Z-score > 3 = severe dilatation
  • "Aortic Dissection Risk: Increases exponentially with diameter > 45-50mm"
    • Annual risk: less than 1% if less than 40mm, ~3% if 45-50mm, ~7% if > 50mm [29,30]

Valve Abnormalities:

• Mitral Valve Prolapse (MVP) (40-80%):

  • Myxomatous degeneration → billowing leaflets
  • "Auscultation: Mid-systolic click ± late systolic murmur (apex, radiates to axilla)"
  • "Echo criteria: Leaflet displacement > 2mm beyond mitral annular plane in parasternal long-axis"
  • "Mitral Regurgitation (MR): Mild-moderate (40%), severe requiring surgery (5-10%)"
  • Can progress over time; ~10% require mitral valve surgery [31]

• Tricuspid Valve Prolapse (20%): Similar pathophysiology, usually less severe

• Aortic Regurgitation (AR) (20-40%):

  • Due to aortic root dilatation → valve annulus stretching
  • "Auscultation: Early diastolic murmur (left sternal border, patient sitting forward)"
  • Severity correlates with degree of aortic root dilatation
  • Severe AR accelerates aortic dilatation (volume overload)

Arrhythmias:

• Mitral Valve Prolapse-Associated: Premature ventricular contractions (PVCs), non-sustained VT
• Supraventricular Arrhythmias: Atrial fibrillation/flutter (especially if significant MR)
• Sudden Cardiac Death: Rare (less than 1%) but can occur, especially with severe MVP/MR [41]

Pulmonary System (10-30%):

• Spontaneous Pneumothorax (5-10% lifetime):

  • Due to rupture of apical blebs/bullae
  • Presents with acute chest pain, dyspnea
  • Often recurrent (50% recurrence after first episode)
  • More common in tall, thin males 15-30 years
  • Requires chest drain ± pleurodesis if recurrent [35]

• Restrictive Lung Disease:

  • Pectus deformity compresses lungs → reduced TLC, FVC
  • Severe scoliosis (Cobb > 50°) → restrictive pattern
  • Usually mild; FVC 70-85% predicted

• Apical Blebs: Detected on CT chest (present in 70% even without pneumothorax history)

• Sleep Apnea: Obstructive (high-arched palate, retrognathia) or central (dural ectasia)

Skin and Soft Tissue (50-70%):

• Striae Atrophicae (Stretch Marks):

  • Appear over shoulders, back, hips, thighs
  • NOT explained by pregnancy, weight gain, or Cushing syndrome
  • Suggest rapid growth with weak dermal collagen support
  • More common in adolescents (40-60%)

• Hernias (20%):

  • "Inguinal (15%): Weak abdominal wall"
  • "Incisional: Poor wound healing after surgery"
  • Umbilical (5%)

• Skin Hyperextensibility: Mild (not as marked as Ehlers-Danlos syndrome)

Nervous System:

• Dural Ectasia (60-92% on MRI):

  • Dilatation of dural sac, most common in lumbosacral region
  • Often asymptomatic
  • "Symptomatic cases: chronic low back pain, proximal leg weakness/numbness, headaches"
  • "MRI findings: Dural sac diameter > 19mm, scalloping of posterior vertebral bodies, anterior meningocele"
  • "Inclusion in Ghent Criteria: worth 2 points on Systemic Score [36]"

• Cervical Spine Instability: Rare but serious; atlantoaxial instability from ligamentous laxity

Craniofacial Features (40-60%):

• Dolichocephaly: Long, narrow skull (reduced cephalic index less than 76%)
• Enophthalmos: Deep-set eyes
• Downslanting Palpebral Fissures: Outer corners of eyes lower than inner
• Malar Hypoplasia: Flat cheekbones
• Retrognathia: Receding chin
• High-Arched Palate: Narrow, V-shaped palate with dental crowding

Diagnosis of "Facial Features" requires 3 out of 5 findings (contributes 1 point to Systemic Score)

---

6. Investigations

Diagnosis and management of Marfan syndrome require a systematic, multidisciplinary approach involving cardiology, ophthalmology, genetics, and often orthopaedics.

Initial Diagnostic Workup

1. Echocardiography (MANDATORY for all suspected cases):

Purpose: Detect aortic root dilatation and valve abnormalities

Protocol:

• Transthoracic Echo (TTE) is first-line in children

• Aortic Root Measurement:

  • Measure at Sinuses of Valsalva in parasternal long-axis view
  • Use leading-edge to leading-edge technique at end-diastole
  • "Measure at 4 levels: Annulus, Sinuses of Valsalva, Sinotubular junction, Ascending aorta"
  • Calculate Z-score using validated nomograms (e.g., Gautier, Campens, or Devereux equations corrected for BSA) [9,10]
  • Z ≥2 = Aortic dilatation (meets Ghent criterion)
  • Z ≥3 = Severe dilatation (requires intensified surveillance)

• Valve Assessment:

  • "Mitral valve: Leaflet thickness, prolapse (> 2mm beyond annular plane), regurgitation severity"
  • "Aortic valve: Leaflet morphology, aortic regurgitation"
  • "Tricuspid valve: Prolapse, regurgitation"

• Left Ventricular Function: Assess for volume overload (if significant AR or MR)

Limitations:

• Acoustic windows may be poor in pectus deformity
• Descending aorta poorly visualized on TTE (requires CT/MRI if dissection suspected)

2. Ophthalmologic Examination (MANDATORY):

Purpose: Detect ectopia lentis and other ocular manifestations

Protocol:

• Slit-Lamp Examination after pharmacological pupillary dilatation (e.g., Tropicamide 1%)

• Performed by ophthalmologist (not optometrist; subtle ectopia lentis easily missed)

• Assess:

  • Lens position (look for iridodonesis, phacodonesis, visible lens edge)
  • Direction of displacement (superotemporal = Marfan; inferonasal = Homocystinuria)
  • Degree of subluxation (mild/moderate/severe)
  • Retinal examination (detachment, high myopia changes)
  • Intraocular pressure (glaucoma screening)

• Refraction: Quantify myopia (> 3 dioptres contributes to Systemic Score)

• Axial Length Measurement (A-scan ultrasound): > 25mm suggests high myopia

Follow-up:

• Annual if no ectopia lentis
• 6-monthly if ectopia lentis present (increased retinal detachment risk)

3. Genetic Testing:

Purpose: Confirm diagnosis, enable family screening, provide prognostic information

Indications:

• All patients meeting clinical criteria for MFS
• Borderline cases where genetic confirmation would influence management
• Family members of confirmed MFS patients (cascade screening)

Testing Strategy:

• First-line: FBN1 gene sequencing (all 65 exons) and deletion/duplication analysis
• Detection rate: 90-95% in clinically definite MFS
• Turnaround time: 3-6 months (varies by laboratory)

Interpretation:

• Pathogenic variant: Confirms diagnosis (even if clinical features borderline)
• Variant of Uncertain Significance (VUS): Common (15-20% of tests); does not confirm or exclude diagnosis; family segregation analysis may help
• No mutation detected: Does NOT exclude MFS (5-10% of clinical MFS have no detectable FBN1 mutation)
  • "Consider: TGFBR1/TGFBR2 (Loeys-Dietz), TGFB2, TGFB3, SMAD3, SKI, COL3A1 (vascular EDS)"

Genetic Counseling:

• Autosomal dominant inheritance: 50% risk to offspring
• De novo mutations: Low recurrence risk (~1-2% due to germline mosaicism)
• Prenatal/preimplantation genetic diagnosis available if pathogenic variant known [37]

Additional Investigations (Selected Cases)

4. MRI Spine (if Systemic Score borderline or symptoms suggestive):

Indication: Detect dural ectasia (contributes 2 points to Systemic Score)

Protocol:

• Lumbosacral MRI (T1 and T2 weighted sequences)
• Measurement of dural sac diameter at S1 level (> 19mm = abnormal)
• Look for: Posterior vertebral body scalloping, anterior meningocele, widening of neural foramina

Prevalence: 60-92% of MFS patients, increases with age [36]

5. Skeletal X-rays (if clinically indicated):

• Chest X-ray:

  • Assess pectus severity (Haller index on CT if surgery planned)
  • Detect scoliosis (measure Cobb angle if present)

• Pelvis X-ray (AP view):

  • "Protrusio Acetabuli: Femoral head center projects medial to ilioischial line (2 points on Systemic Score)"
  • Useful if Systemic Score borderline

• Hand X-ray:

  • Calculate Metacarpal Index (length/width ratio of metacarpals 2-5)

  • 8.4 suggests arachnodactyly (not in Ghent criteria, but supports diagnosis)

• Spine X-ray (standing PA and lateral):

  • Measure scoliosis Cobb angle (> 20° = 1 point on Systemic Score)
  • Assess for spondylolisthesis

6. CT or MRI Angiography of Aorta:

Indications:

• Symptoms suggestive of aortic dissection (chest/back pain, syncope, pulse deficit)
• Pre-surgical planning (measure entire aorta from root to iliac bifurcation)
• Poor echocardiographic windows
• Assessment of descending thoracic and abdominal aorta if echo shows ascending dilatation

Protocol:

• CT Angiography (CTA): Rapid, excellent spatial resolution, requires IV contrast and radiation
• MR Angiography (MRA): No radiation, no nephrotoxic contrast, longer acquisition time
  • Preferred in children for serial surveillance if repeated imaging needed

Measurements: Assess aortic diameter at multiple levels, compare to normative data

7. Cardiovascular MRI (Cardiac MRI):

Indications:

• Assess LV volumes and function if significant valve regurgitation
• Quantify regurgitant fraction (AR or MR severity)
• Late gadolinium enhancement (LGE): Detect myocardial fibrosis (prognostic in severe MR)

8. Exercise Testing (Cardiopulmonary Exercise Test - CPET):

Indications:

• Establish safe exercise limits for children/adolescents
• Assess functional capacity if significant valve disease or restrictive lung disease
• Detect exercise-induced arrhythmias

Protocol:

• Treadmill or cycle ergometer with continuous ECG, BP monitoring, gas exchange analysis
• Measure: Peak VO2, anaerobic threshold, BP response, arrhythmias

9. Holter Monitoring (24-48 hour ECG):

Indications:

• Palpitations or syncope
• Significant MVP (risk of ventricular arrhythmias)
• Pre-operative assessment

10. Urinary Homocysteine (if atypical features):

Indication: Exclude Homocystinuria (CBS deficiency)

Differential features:

• Homocystinuria: Intellectual disability, thromboembolic events, downward lens dislocation, ELEVATED urinary homocysteine
• Marfan: Normal intellect, no thrombosis, upward lens dislocation, NORMAL homocysteine [8]

11. Biomarkers (Research/Emerging):

Currently NOT part of routine clinical practice, but under investigation:

• TGF-beta levels (plasma): Elevated in MFS, may correlate with disease severity
• Matrix Metalloproteinases (MMPs): MMP-2, MMP-9 elevated in aortic tissue
• Soluble Fibrillin-1 fragments: May predict aortic dilatation rate
• microRNAs: Specific profiles associated with aortic disease progression [42]

Surveillance Investigations (After Diagnosis)

Annual Echocardiography:

• For ALL patients with MFS, regardless of baseline aortic diameter
• More frequent (6-monthly) if:
  • Aortic root Z-score > 3
  • Rapid progression (> 3mm/year or Z-score increase > 0.5/year)
  • Moderate-severe aortic or mitral regurgitation
  • During pregnancy (monthly)
  • Adolescent growth spurt [43]

Annual Ophthalmology Review:

• Monitor for development/progression of ectopia lentis
• Screen for retinal detachment, glaucoma
• Update refractive correction

Genetic Counseling:

• At diagnosis
• Before family planning (preconception counseling)

---

7. Management

Management of Marfan syndrome requires lifelong, multidisciplinary care focused on preventing aortic dissection, managing valve disease, monitoring skeletal and ocular manifestations, and optimizing quality of life.

Management Algorithm

           MARFAN SYNDROME DIAGNOSIS
                      ↓
         ┌────────────┴────────────┐
         │  BASELINE ASSESSMENT    │
         │  • Echo (Aortic Z-score)│
         │  • Ophthalmology (EL)   │
         │  • Genetics (FBN1)      │
         │  • Skeletal Survey      │
         └────────────┬────────────┘
                      ↓
         ┌────────────┴──────────────────┐
         │ CARDIOVASCULAR PROPHYLAXIS     │
         │ • Beta-Blocker (1st line)      │
         │   - Atenolol 1-2 mg/kg/day     │
         │   - Target HR less than 60 bpm (rest)   │
         │   - Reduces dP/dt (shear stress)│
         │ • ARB (Alternative/Adjunct)    │
         │   - Losartan 0.5-1 mg/kg/day   │
         │   - Blocks TGF-beta signalling │
         │   - Add if BB intolerant or    │
         │     progressive dilatation     │
         └────────────┬──────────────────┘
                      ↓
         ┌────────────┴──────────────────┐
         │ ANNUAL SURVEILLANCE            │
         │ • Echo (Aortic root, valves)   │
         │ • Ophthalmology                │
         │ • Skeletal (scoliosis)         │
         │ • Lifestyle counseling         │
         └────────────┬──────────────────┘
                      ↓
         ┌────────────┴──────────────────┐
         │ SURGICAL THRESHOLD REACHED?    │
         │ • Aorta ≥50mm (Adult)          │
         │ • Aorta ≥45mm + Family Hx      │
         │   dissection                   │
         │ • Rapid growth > 3-5mm/year     │
         │ • Severe AR or MR              │
         └────────────┬──────────────────┘
              ┌───────┴───────┐
              NO             YES
              ↓               ↓
      CONTINUE MEDS    CARDIAC SURGERY
      SURVEILLANCE     • Aortic Root:
                         - Valve-Sparing (David/Yacoub)
                         - Composite Graft (Bentall)
                       • Mitral Valve:
                         - Repair (preferred)
                         - Replacement (if not repairable)

Cardiovascular Medical Management

Goal: Reduce hemodynamic stress on aortic wall, slow aortic dilatation, prevent dissection

1. Beta-Blockers (FIRST-LINE):

Mechanism:

• Reduce heart rate → increase diastolic time → reduce cardiac output
• Reduce dP/dt (rate of change of pressure): Primary mechanism of benefit
  • Lower dP/dt = less shear stress on aortic wall during systole
• Decrease blood pressure → reduce wall tension

Evidence:

• Historical Studies: Observational data showed beta-blockers slow aortic dilatation and reduce dissection/death
• Meta-analysis (Cochrane 2012): Beta-blockers reduce rate of aortic dilatation by 0.77 mm/year (95% CI 0.29-1.24 mm/year) [44]
• Limitations: No large RCTs (unethical to have placebo arm given observational benefit)

Drug Choice:

• Atenolol (most commonly used):

  • Selective beta-1 blocker
  • Long half-life (once or twice daily dosing)
  • "Dose: 1-2 mg/kg/day PO (max 100 mg/day)"
  • "Target: Resting HR less than 60-70 bpm, exercise HR less than 100 bpm"

• Propranolol (alternative):

  • Non-selective beta-blocker
  • "Dose: 2-4 mg/kg/day PO divided BID-TID (max 320 mg/day)"
  • May be preferred in children with concurrent migraines

• Nebivolol (emerging evidence):

  • Highly selective beta-1 blocker with NO-mediated vasodilation
  • May have additional anti-fibrotic effects
  • Limited paediatric data

Monitoring:

• Heart Rate: Measure resting HR at each visit
  • "Target: less than 60 bpm at rest (adults), less than 70 bpm (children less than 10 years)"
  • Exercise HR should not exceed 100 bpm (exercise testing to confirm)
• Blood Pressure: Monitor for hypotension (dizzy, fatigue)
• Adverse Effects:
  • Fatigue, exercise intolerance (most common)
  • Bronchospasm (avoid in asthma; use selective beta-1 blocker)
  • Cold extremities
  • Depression, sleep disturbance
• Adherence: Critical; non-adherence associated with worse outcomes [45]

Contraindications:

• Severe asthma (relative; selective beta-1 blockers may be tolerated)
• High-grade AV block
• Severe bradycardia

2. Angiotensin Receptor Blockers (ARBs) - Alternative or Adjunctive:

Mechanism:

• Block AT1 receptor → reduce angiotensin II signaling → vasodilation, BP reduction
• Inhibit TGF-beta signaling: Key mechanism in MFS
  • Angiotensin II stimulates TGF-beta; ARBs block this pathway
  • May address root cause (TGF-beta dysregulation) rather than just symptoms [11,12]

Evidence:

• Mouse Models: Losartan prevented aortic aneurysm progression in Marfan mice (proof-of-concept) [27]

• Lacro et al. NEJM 2014: RCT comparing Atenolol vs Losartan in children/young adults (608 patients, 3 years)

  • "Primary outcome: Aortic root Z-score change"
  • "Result: NO significant difference between groups (both slowed dilatation)"
  • "Conclusion: Losartan non-inferior to atenolol; both are effective [46]"

• COMPARE Trial (2022): Losartan vs placebo (added to beta-blocker) in adults

  • "Result: No additional benefit of losartan over beta-blocker alone"
  • Suggests ARBs may be alternative but not necessarily superior to beta-blockers [47]

Drug Choice:

• Losartan (most evidence):

  • "Dose: 0.5-1.0 mg/kg/day PO once daily (max 100 mg/day)"
  • "Target: BP less than 95th percentile for age"

• Irbesartan (alternative):

  • Longer half-life, may improve adherence
  • "Dose: 75-300 mg PO once daily"

Monitoring:

• Blood Pressure: Monitor for hypotension
• Renal Function: Check creatinine, potassium (ARBs can cause hyperkalemia, especially if combined with ACE inhibitors)
• Adverse Effects: Generally well-tolerated; dizziness, fatigue, cough (less than ACE inhibitors)

Current Consensus (2023):

• Beta-blockers remain FIRST-LINE (stronger historical evidence, proven mortality benefit)
• ARBs are EQUIVALENT ALTERNATIVE if beta-blockers contraindicated/not tolerated
• Combination beta-blocker + ARB: May be considered if progressive dilatation despite monotherapy, but evidence limited [48]

3. ACE Inhibitors (Limited Role):

• Mechanism: Similar to ARBs (reduce angiotensin II), but also affect bradykinin
• Evidence: Less robust than ARBs in MFS
• Use: Generally reserved for patients with LV dysfunction (severe MR/AR)
• Adverse Effects: Cough (10-20%), angioedema (rare)

4. Calcium Channel Blockers (NOT RECOMMENDED):

• Reason: Increase dP/dt (reflex tachycardia) → may worsen aortic stress
• Exception: May be used for hypertension control if beta-blockers/ARBs insufficient, but ONLY in combination (never as monotherapy)

Cardiovascular Surgical Management

Goal: Prevent aortic dissection/rupture, manage severe valve regurgitation

Aortic Root Replacement:

Indications (Adult Criteria):

1. Aortic Root Diameter ≥50mm
2. Aortic Root Diameter ≥45mm AND:
   • Family history of aortic dissection
   • Rapid growth > 3-5 mm/year
   • Severe aortic regurgitation
   • Planned pregnancy
3. Aortic Root Diameter ≥40mm if concomitant valve surgery needed

Paediatric Considerations:

• Absolute diameter thresholds less applicable (body size varies)
• Consider Z-score and rapid growth rate (> 0.5 Z-score units/year or > 5mm/year)
• Individualized decision-making; most children/adolescents do not require surgery
• Defer surgery until late adolescence/early adulthood if possible (to allow native valve preservation) [49]

Surgical Options:

1. Valve-Sparing Aortic Root Replacement (Preferred):

   • David Procedure (reimplantation technique):

     • Aortic root replaced with synthetic graft (Dacron)
     • Native aortic valve leaflets preserved and reimplanted
     • Advantages: Avoids anticoagulation, preserves native valve
     • Disadvantages: Technically demanding, risk of late AR (10-15% at 10 years)
     • Outcomes: 10-year survival > 95%, freedom from reoperation 85-90% [50]

   • Yacoub Procedure (remodeling technique):

     • Similar concept but different technique
     • Less commonly used than David

2. Composite Valve-Graft Replacement (Bentall Procedure):

   • Aortic root + valve replaced with composite graft (mechanical or bioprosthetic valve sewn into Dacron graft)
   • Coronary arteries reimplanted (Cabrol technique)
   • Indications: Valve-sparing not possible (bicuspid aortic valve, severe leaflet pathology)
   • Mechanical Valve:
     • Advantages: Durability (lasts lifetime)
     • Disadvantages: Lifelong anticoagulation (warfarin; target INR 2-3), bleeding/thrombosis risk, contraindicated in pregnancy
   • Bioprosthetic Valve:
     • Advantages: No anticoagulation required
     • Disadvantages: Degeneration (requires redo surgery in 10-15 years), not ideal for young patients
   • Outcomes: 10-year survival > 90%, but anticoagulation burden [51]

Operative Mortality:

• Centers of excellence: less than 2% for elective aortic root replacement
• Emergency surgery (dissection): 10-25%
• Key Point: Elective surgery far safer than emergency; hence importance of surveillance

Post-Operative Surveillance:

• Annual echo: Assess graft, residual aorta, valve function
• Lifelong monitoring: Remainder of aorta still at risk (descending thoracic, abdominal aorta can dilate)
• Continue beta-blocker/ARB therapy post-operatively

Mitral Valve Surgery:

Indications:

1. Severe Mitral Regurgitation (MR) with:
   • Symptoms (dyspnea, exercise intolerance)
   • LV dysfunction (LVEF less than 60%)
   • LV dilatation (LVESD > 40mm)
2. Asymptomatic Severe MR if new-onset atrial fibrillation or pulmonary hypertension

Surgical Options:

1. Mitral Valve Repair (Preferred):

   • Leaflet resection/plication, chordal transfer, annuloplasty ring
   • Advantages: Preserves native valve, no anticoagulation (unless AF), better long-term outcomes
   • Success Rate: 80-90% in expert centers

2. Mitral Valve Replacement:

   • If repair not feasible (severe leaflet destruction)
   • Mechanical vs bioprosthetic considerations same as aortic

Outcomes:

• Repair: 10-year survival > 85%, freedom from reoperation 70-80%
• Replacement: Similar survival, but anticoagulation burden if mechanical [52]

Skeletal Management

Scoliosis:

• Monitoring: Annual standing spine X-rays during growth
• Bracing: If Cobb angle 20-40° and still growing (controversial efficacy in MFS; compliance often poor)
• Surgery: If Cobb angle > 40-50° and progressive
  • Posterior spinal fusion with instrumentation
  • "Timing: Ideally after growth completion (to maximize final height)"
  • "Complications: Higher in MFS (dural ectasia complicates surgery) [53]"

Pectus Deformity:

• Indications for Surgery:
  • Severe excavatum with cardiac compression (Haller index > 3.25)
  • Severe carinatum with psychosocial impact
  • Progressive restrictive lung disease
• Surgical Options:
  • Nuss procedure (minimally invasive, bar placement) for pectus excavatum
  • Ravitch procedure (open repair) for carinatum or complex deformities
• Timing: Typically adolescence (age 12-16 years)

Pes Planus / Joint Pain:

• Orthotics: Custom insoles for flat feet
• Physiotherapy: Strengthening exercises for joint stability
• Analgesia: NSAIDs for chronic pain (use caution with anticoagulation)
• Activity Modification: Avoid high-impact activities

Ocular Management

Ectopia Lentis:

• Conservative: Update refractive correction (glasses/contact lenses)
• Surgical: Lens extraction + intraocular lens (IOL) implantation if:
  • Severe visual impairment
  • Monocular vision (amblyopia risk)
  • Lens-induced glaucoma
  • Patient age > 5 years (to allow eye growth)

Retinal Detachment:

• Emergency: Requires urgent vitreoretinal surgery (scleral buckle, vitrectomy)
• Prevention: Avoid head trauma, regular ophthalmology surveillance

Glaucoma:

• Medical: Topical drops (prostaglandin analogues, beta-blockers, carbonic anhydrase inhibitors)
• Surgical: Trabeculectomy if refractory

Lifestyle Modifications

Exercise Recommendations:

Rationale:

• Isometric exercise → sudden BP spikes → increased wall stress → dissection risk
• Contact sports → chest trauma → aortic rupture or lens dislocation risk
• Moderate aerobic → gradual BP increase, better tolerated, cardiovascular benefits [54]

Pregnancy Counseling:

• Pre-Pregnancy Risk Stratification:

  • Aortic root less than 40 mm: Low risk (~1% dissection)
  • 40-45 mm: Moderate risk (~5%), pregnancy feasible with intensive monitoring

  • 45 mm: High risk (~10%), pregnancy contraindicated

  • "Prior dissection/surgery: Individualized assessment"

• Management During Pregnancy:

  • Continue beta-blocker (atenolol safe in 2nd/3rd trimester; switch from ACE/ARB in 1st trimester)
  • Monthly echocardiography (monitor aortic root)
  • Avoid vagal maneuvers during delivery (risk of aortic dissection)
  • "Mode of Delivery:"
    • Vaginal: If aortic root less than 40mm, epidural analgesia, assisted 2nd stage (forceps/vacuum) to avoid Valsalva
    • Caesarean: If aortic root > 45mm, severe valve disease, or obstetric indications
  • "Postpartum: HIGH RISK PERIOD (hemodynamic changes); continue monitoring 6 months [20,21]"

Endocarditis Prophylaxis:

• NOT routinely recommended for isolated MVP or aortic root dilatation
• Indicated for:
  • Prosthetic valves (post-Bentall or mitral replacement)
  • Prior endocarditis
  • Unrepaired cyanotic congenital heart disease
• Regimen: Amoxicillin 2g PO 1 hour before dental procedures

Psychosocial Support:

• Diagnosis Impact: Chronic illness, body image issues (tall, thin, skeletal features), anxiety about sudden death
• Peer Support: National Marfan Foundation (US), Marfan Trust (UK)
• Mental Health: Screen for depression/anxiety; refer for counseling if needed
• Transition to Adult Care: Structured transition programs (age 16-18) to ensure continuity [55]

Multidisciplinary Team

Optimal care requires coordination between:

• Paediatric/Adult Cardiologist: Cardiovascular surveillance, medical management
• Cardiac Surgeon: Aortic/valve surgery when indicated
• Ophthalmologist: Annual eye exams, manage ectopia lentis
• Geneticist: Diagnosis, family screening, genetic counseling
• Orthopaedic Surgeon: Scoliosis/pectus management
• Rheumatologist: Joint pain management
• Primary Care Physician/Paediatrician: Coordination, general health
• Clinical Nurse Specialist: Patient education, adherence support

---

8. Complications

Cardiovascular Complications

Aortic Dissection (Type A):

• Incidence: 1-2% per year if untreated, risk increases with aortic diameter
• Mechanism: Tear in intimal layer → blood enters aortic media → false lumen formation → propagation
• Classification:
  • "Type A (Stanford): Involves ascending aorta (60% of MFS dissections)"
  • "Type B: Descending aorta only (40%)"
• Presentation: ACUTE, SEVERE tearing/ripping chest pain radiating to back, syncope, pulse deficit, acute AR murmur, stroke (if carotid dissection)
• Diagnosis: CT Angiography (gold standard), TEE
• Management: Type A = SURGICAL EMERGENCY (mortality 1% per hour untreated), Type B = medical (unless complicated)
• Mortality: 50% at 48 hours if untreated, 10-20% operative mortality even with surgery [56]

Aortic Rupture:

• Catastrophic complication of dissection or free wall rupture
• Usually fatal; presents with sudden collapse, hemopericardium (tamponade)

Endocarditis:

• Risk: Increased in patients with mitral/aortic regurgitation or prosthetic valves
• Organisms: Streptococcus viridans (dental), Staphylococcus aureus
• Prevention: Antibiotic prophylaxis ONLY for prosthetic valves or prior endocarditis
• Complications: Valve destruction, embolic phenomena, heart failure

Arrhythmias:

• Mitral Valve Prolapse-Associated: PVCs, non-sustained VT (usually benign)
• Atrial Fibrillation: If severe MR → LA dilatation
• Sudden Cardiac Death: Rare (less than 1%), associated with severe MVP, ventricular arrhythmias

Heart Failure:

• Due to severe aortic or mitral regurgitation
• Neonatal Marfan: Presents with acute heart failure in first months of life
• Adults: Chronic volume overload → LV dilatation → systolic dysfunction

Ocular Complications

Retinal Detachment:

• Incidence: 5-11% lifetime (vs 0.06% general population)
• Mechanism: High myopia → vitreous traction; ectopia lentis → altered vitreous dynamics
• Presentation: Flashes, floaters, peripheral visual field loss ("curtain")
• Management: Emergency vitreoretinal surgery
• Outcome: Good if treated promptly; permanent vision loss if delayed [34]

Glaucoma:

• Incidence: 10% of MFS patients
• Types:
  • Open-angle (chronic, associated with myopia)
  • Angle-closure (if dislocated lens blocks trabecular meshwork)
  • Lens-induced (phacomorphic)
• Management: Medical (drops) or surgical (trabeculectomy)

Blindness:

• Due to untreated retinal detachment, glaucoma, or amblyopia from uncorrected ectopia lentis
• Preventable with regular ophthalmology surveillance

Pulmonary Complications

Spontaneous Pneumothorax:

• Incidence: 5-10% lifetime, often recurrent (50% recurrence after first episode)
• Presentation: Acute pleuritic chest pain, dyspnea, reduced breath sounds
• Management: Small (less than 20%) = observation; Large (> 20%) = chest drain ± pleurodesis
• Differential: Must exclude aortic dissection (both present with chest pain in MFS)

Restrictive Lung Disease:

• Due to severe scoliosis (Cobb > 50°) or pectus excavatum
• Spirometry: FVC less than 80% predicted, normal FEV1/FVC ratio
• Impact: Exercise limitation, sleep apnea

Obstructive Sleep Apnea:

• Due to craniofacial features (high-arched palate, retrognathia, midface hypoplasia)
• Diagnosis: Polysomnography (sleep study)
• Management: CPAP, weight loss, consider adenotonsillectomy if indicated

Skeletal Complications

Progressive Scoliosis:

• Incidence: 60% have some degree of scoliosis; 20% require surgery
• Complications of Surgery: Dural tear (dural ectasia), CSF leak, infection, neurological injury
• Long-term: Early degenerative disc disease, chronic pain

Protrusio Acetabuli:

• Incidence: 40% on imaging
• Symptomatic: 10-15% (hip pain, reduced range of motion)
• Management: Conservative (analgesia, physiotherapy); total hip replacement if severe osteoarthritis

Recurrent Joint Dislocations:

• Shoulder, patella, fingers due to ligamentous laxity
• Management: Physiotherapy (strengthening), avoid high-risk activities, surgical stabilization if recurrent

Neurological Complications

Dural Ectasia (Symptomatic):

• Symptoms: Chronic low back pain, radiculopathy (leg numbness/weakness), headaches
• Mechanism: CSF pulsations → erosion of vertebral bone → nerve root compression
• Management: Conservative (analgesia, physiotherapy); rarely requires surgical decompression

Cervical Spine Instability:

• Rare but serious; atlantoaxial instability from ligamentous laxity
• Risk: Spinal cord injury from minor trauma
• Screening: Lateral cervical spine X-rays (flexion/extension) if neck pain or neurological symptoms

Pregnancy Complications (Maternal)

Aortic Dissection:

• Peak Risk: 3rd trimester and first month postpartum
• Mechanism: Increased blood volume (50% increase), hormonal changes (progesterone weakens connective tissue)
• Outcome: Maternal mortality 10-25% if dissection occurs

Preterm Delivery:

• Incidence: 28% (vs 11% general population)
• Due to cervical insufficiency (connective tissue laxity)

Fetal/Neonatal Implications:

• 50% inheritance risk (if mother affected)
• Fetal echocardiography (20-24 weeks) to assess cardiac structures
• Genetic testing of child after birth if mother known to have pathogenic FBN1 variant

Other Complications

Surgical Complications:

• Poor Wound Healing: Connective tissue disorder → dehiscence, incisional hernias
• Bleeding: Tissue fragility; careful surgical technique required

Anaesthetic Complications:

• Atlantoaxial instability: Risk of spinal cord injury during intubation
• Dural ectasia: Technical difficulty with spinal/epidural anaesthesia
• Cardiovascular instability: Careful monitoring required [57]

---

9. Prognosis and Outcomes

Natural History (Untreated)

Historical Data (Pre-1970s):

• Median Survival: 32 years (range 20-40 years)
• Mortality: 90% cardiovascular (aortic dissection/rupture 60%, heart failure 30%)
• Cause of Death: Aortic dissection (type A) most common (45-60% of deaths)

Contemporary Outcomes (Modern Management)

Life Expectancy:

• With medical surveillance and surgical intervention: Life expectancy now approaches that of general population
• Near-Normal Lifespan: Studies show median survival > 70 years (vs 32 years pre-treatment era)
• Improvement: Attributable to:
  • Beta-blockers/ARBs (slow aortic dilatation)
  • Echocardiographic surveillance (detect dilatation early)
  • Prophylactic aortic surgery (prevent dissection)
  • Improved surgical techniques (valve-sparing procedures) [3,4]

Cardiovascular Outcomes:

• Aortic Dissection Risk: Reduced from 40% lifetime to less than 5% with modern management
• Surgical Survival: Elective aortic root replacement > 95% 10-year survival in expert centers
• Post-Surgical QoL: Good; most patients return to normal activities (with exercise restrictions)

Prognostic Factors

Favorable Prognostic Factors:

• Early Diagnosis: Enables early medical therapy, surveillance
• Adherence to Beta-Blocker/ARB: Reduces aortic dilatation rate
• Regular Surveillance: Early detection of progressive dilatation allows timely surgery
• Elective Surgery: Planned aortic surgery has far better outcomes than emergency (2% vs 25% mortality)
• Absence of Neonatal Features: Neonatal Marfan has poor prognosis (40-90% mortality without surgery)

Adverse Prognostic Factors:

• Neonatal Presentation: Severe valve regurgitation, heart failure in infancy (poor outcome)
• Family History of Dissection: Increased risk (consider surgery at lower diameter threshold: 45mm vs 50mm)
• Rapid Aortic Growth: > 5 mm/year or > 0.5 Z-score/year (requires closer surveillance, earlier surgery)
• Non-Adherence to Medications: Increased dissection risk
• Female Sex in Pregnancy: Aortic root > 40mm at conception increases dissection risk 10-fold [58]

Quality of Life

Physical Function:

• Exercise Limitations: Restricted from competitive/contact sports, but can engage in recreational aerobic activities
• Skeletal Manifestations: Chronic pain (scoliosis, joint laxity), may limit function
• Vision: Correctable with glasses/lenses in most cases; surgery may restore vision if ectopia lentis severe

Psychosocial Impact:

• Body Image: Tall stature, skeletal features, surgical scars may affect self-esteem (especially adolescents)
• Anxiety: Fear of sudden death (dissection), need for lifelong monitoring
• Peer Support: National Marfan Foundation and similar organizations provide community, resources
• Employment/Insurance: May face discrimination; genetic discrimination laws (GINA in US) provide some protection [55]

Reproductive Considerations:

• Males: Can father children without restrictions (though 50% inheritance risk)
• Females: Pregnancy feasible if aortic root less than 40mm with intensive monitoring; contraindicated if > 45mm
• Genetic Options: Preimplantation genetic diagnosis (PGD) allows selection of unaffected embryos (IVF required)

Long-Term Surveillance (Lifelong)

Cardiovascular:

• Annual Echocardiography: All patients, regardless of surgical history (remainder of aorta still at risk)
• 6-Monthly Echo: If aortic root Z> 3, rapid progression, significant valve disease, pregnancy

Ophthalmology:

• Annual Review: Screen for ectopia lentis progression, retinal detachment, glaucoma

Skeletal:

• Annual Spine X-rays: During growth (monitor scoliosis progression)
• PRN: If new symptoms (pain, deformity)

Genetics:

• Family Screening: First-degree relatives should undergo clinical evaluation + genetic testing if proband's mutation known

---

10. Evidence and Guidelines

Key Guidelines

Landmark Evidence

1. Loeys et al. (J Med Genet 2010) - Revised Ghent Nosology:

• Design: International expert consensus, systematic review of diagnostic accuracy
• Key Finding: Simplified diagnostic criteria; emphasized aortic root dilatation + ectopia lentis as cardinal features
• Impact: Improved diagnostic accuracy (sensitivity 86%, specificity 98%), reduced misdiagnosis of related disorders (Loeys-Dietz, MASS phenotype)
• Systemic Score: Introduced quantitative scoring system (≥7 points = positive)
• Clinical Implication: Now universally adopted diagnostic standard [5]

2. Shores et al. (NEJM 1994) - Beta-Blockers and Aortic Dilatation:

• Design: Randomized controlled trial, propranolol vs no treatment, 70 patients, 10 years
• Key Finding: Propranolol significantly reduced rate of aortic dilatation (1.04 mm/year vs 1.83 mm/year, pless than 0.001) and composite endpoint (aortic regurgitation, dissection, surgery, death)
• Impact: Established beta-blockers as first-line medical therapy
• Limitation: Small sample size, open-label design [63]

3. Lacro et al. (NEJM 2014) - Atenolol vs Losartan (Pediatric Heart Network Study):

• Design: Randomized controlled trial, atenolol vs losartan, 608 patients (age 6 months-25 years), 3 years
• Primary Outcome: Change in aortic root Z-score
• Key Finding: NO significant difference between atenolol and losartan (both reduced Z-score by ~0.1 units)
  • "Atenolol: -0.139 Z-score/year"
  • "Losartan: -0.107 Z-score/year"
  • "Difference: p=0.08 (not significant)"
• Secondary Outcomes: No difference in aortic dissection, surgery, or death (rates very low in both groups)
• Impact:
  • Refuted earlier enthusiasm that losartan (TGF-beta inhibitor) was superior to beta-blockers
  • Established losartan as equivalent alternative (not superior) to atenolol
  • Both drugs remain acceptable first-line options
• Clinical Implication: Beta-blockers remain first-line (stronger historical evidence); losartan used if beta-blockers contraindicated/not tolerated [46]

4. COMPARE Trial (Mullen et al., JAMA Cardiol 2022) - Losartan Added to Beta-Blocker:

• Design: Randomized placebo-controlled trial, losartan vs placebo (both groups on beta-blocker), 233 adults, 3 years
• Primary Outcome: Aortic root growth rate
• Key Finding: NO additional benefit of losartan when added to beta-blocker (aortic root growth 0.76 mm/year losartan vs 0.82 mm/year placebo, p=0.49)
• Impact: Combination therapy (beta-blocker + ARB) NOT superior to monotherapy
• Clinical Implication: Avoid polypharmacy unless monotherapy inadequate [47]

5. Gott et al. (Circulation 1999) - Surgical Outcomes and Aortic Diameter:

• Design: Retrospective cohort, 675 patients, 31 years
• Key Finding:
  • Aortic dissection risk increases exponentially with diameter
  • 10-year risk: 3% if less than 40mm, 31% if 40-49mm, 74% if ≥50mm
  • "Elective surgical mortality: 1.5%; emergency (dissection) mortality: 11.7%"
• Impact: Established 50mm threshold for elective surgery (45mm if family history)
• Clinical Implication: Prophylactic surgery at 50mm prevents dissection with acceptable risk [64]

6. David et al. (J Thorac Cardiovasc Surg 1992, Long-term follow-up 2013) - Valve-Sparing Aortic Root Replacement:

• Design: Prospective case series, > 1000 patients, > 20 years follow-up
• Key Finding:
  • Valve-sparing (David procedure) feasible with excellent outcomes
  • 10-year survival: 96%
  • "Freedom from aortic regurgitation ≥3+: 85%"
  • "Freedom from reoperation: 89%"
• Impact: Established valve-sparing as preferred technique (avoids anticoagulation)
• Clinical Implication: Bentall (composite graft) now reserved for cases where valve-sparing not feasible [50]

7. Judge et al. (Lancet 2005) - TGF-beta Hypothesis:

• Design: Mouse model (Fbn1 mutant mice), molecular studies
• Key Finding:
  • Elevated TGF-beta signaling in aortic tissue of Marfan mice
  • TGF-beta neutralizing antibodies prevented aortic aneurysm
  • Losartan (ARB, inhibits TGF-beta) prevented aortic dilatation
• Impact: Paradigm shift in understanding pathophysiology (not just structural defect, but signaling dysregulation)
• Clinical Implication: Mechanistic rationale for ARBs (losartan); led to clinical trials [27]

8. Meijboom et al. (Circulation 2006) - Aortic Stiffness and Beta-Blockers:

• Design: Observational cohort, 711 patients, median 9.7 years
• Key Finding:
  • Beta-blockers reduced risk of combined endpoint (death, aortic dissection, cardiac surgery) by 72% (HR 0.28, pless than 0.001)
  • Benefit greatest in those with aortic root > 40mm
• Impact: Strongest observational evidence for beta-blocker efficacy
• Clinical Implication: All patients should receive beta-blockers unless contraindicated [65]

9. Roman et al. (Circulation 1993) - Z-Score Calculation and Normative Data:

• Design: Cross-sectional study, normative echocardiographic data, 52,204 patients
• Key Finding: Published aortic root normative values adjusted for age and BSA; developed Z-score methodology
• Impact: Enabled pediatric diagnosis (absolute diameter thresholds inadequate in children)
• Clinical Implication: Z-score ≥2 is diagnostic criterion in Revised Ghent Nosology [9]

10. Milewicz et al. (Nat Rev Cardiol 2017) - Genetic Testing and Diagnosis:

• Design: Review of 3000+ FBN1 mutations, genotype-phenotype analysis
• Key Finding:
  • FBN1 mutations identified in 90-95% of clinically diagnosed MFS
  • No clear genotype-phenotype correlation (except exons 24-32 → neonatal MFS)
  • 5-10% of clinical MFS have no detectable FBN1 mutation
• Impact: Genetic testing aids diagnosis but clinical criteria remain paramount
• Clinical Implication: Negative genetic test does NOT exclude MFS if clinical criteria met [37]

Emerging Evidence (2020-2026)

Biomarkers:

• Circulating TGF-beta, MMPs: Potential prognostic markers for aortic dilatation rate (under investigation)
• microRNAs: Specific signatures (miR-29, miR-133) correlate with disease severity [42]

Pharmacotherapy:

• Celiprolol (beta-blocker with vasodilatory properties): Showed benefit in vascular EDS; trials in MFS ongoing
• Doxycycline (MMP inhibitor): Mouse models promising; human trials inconclusive

Surgical Techniques:

• Personalized External Aortic Root Support (PEARS): Custom-made external mesh support for aortic root; early results promising (avoids opening aorta, preserves native valve)
• TAVR (Transcatheter Aortic Valve Replacement): Not currently recommended in MFS (young patients, connective tissue disorder), but under study for high-risk cases [66]

---

11. Patient and Layperson Explanation

What is Marfan Syndrome?

Marfan Syndrome is a genetic condition that affects the body's connective tissue. Connective tissue is like the "glue" that holds the body together—it's found in bones, ligaments, blood vessels, eyes, and many other parts of the body.

In Marfan Syndrome, the "glue" is a bit weaker and stretchier than normal. This is because of a change (called a mutation) in a gene called FBN1, which makes a protein called Fibrillin-1. Fibrillin-1 is an important part of connective tissue, so when it doesn't work properly, various parts of the body are affected.

How is Marfan Syndrome Inherited?

Marfan Syndrome is inherited in an autosomal dominant pattern. This means:

• If one parent has Marfan Syndrome, each child has a 50% chance of inheriting it.
• It affects males and females equally.
• In about 1 in 4 cases, Marfan Syndrome happens for the first time in a family due to a new mutation (called a de novo mutation). This means the parents don't have Marfan, but the child does.

What Parts of the Body Does Marfan Affect?

Marfan Syndrome can affect many parts of the body, but the three main areas are:

1. Bones and Joints (Skeletal System):

• People with Marfan are often tall and thin, with long arms, legs, fingers, and toes (called arachnodactyly, meaning "spider-like fingers").
• The chest may be sunken inward (pectus excavatum) or stick outward (pectus carinatum).
• The spine may curve sideways (scoliosis).
• Joints may be very flexible or "loose" (joint hypermobility), which can lead to joint pain or dislocations.
• Flat feet (pes planus) are common.

2. Eyes (Ocular System):

• The lens of the eye (the clear part that helps you focus) may slip out of place (ectopia lentis). This can cause blurry vision or require glasses with very strong lenses.
• Severe nearsightedness (myopia) is common.
• There is a higher risk of retinal detachment (where the back of the eye pulls away, causing vision loss).
• Glaucoma (increased pressure in the eye) can also occur.

3. Heart and Blood Vessels (Cardiovascular System):

• This is the most serious part. The main blood vessel leaving the heart (the aorta) can become stretched or enlarged (aortic root dilatation).
• If the aorta stretches too much, it can tear (called an aortic dissection). This is a life-threatening emergency.
• The valves of the heart (especially the mitral valve) may not close properly (mitral valve prolapse), causing blood to leak backward (regurgitation).

Why is the Heart Problem So Serious?

The aorta is the largest artery in the body. It carries oxygen-rich blood from the heart to the rest of the body. In Marfan Syndrome, the walls of the aorta are weaker, so over time, the aorta can stretch like a balloon.

If the aorta gets too large, it can tear (dissect). This is extremely dangerous and can be fatal if not treated immediately with emergency surgery. That's why people with Marfan Syndrome need regular heart checks (echocardiograms) to monitor the size of the aorta.

How is Marfan Syndrome Diagnosed?

Doctors use a set of criteria called the Revised Ghent Nosology (2010) to diagnose Marfan Syndrome. Diagnosis is based on:

1. Physical Exam: Looking for skeletal features (tall stature, long limbs, flexible joints, chest deformity, etc.).
2. Eye Exam: Checking for lens dislocation (ectopia lentis) using a special light (slit-lamp examination).
3. Heart Ultrasound (Echocardiogram): Measuring the size of the aorta. A measurement called a Z-score is used to see if the aorta is larger than normal for the person's age and size.
4. Genetic Test: A blood test to look for a mutation in the FBN1 gene. This can confirm the diagnosis.
5. Family History: If a parent, sibling, or child has Marfan Syndrome, it increases the likelihood.

What is the Treatment?

While there is no cure for Marfan Syndrome, there are very effective treatments to prevent serious complications:

Medications:

• Beta-Blockers (e.g., atenolol): These medicines slow down the heart rate and reduce the force of the heartbeat. This lowers the pressure on the aorta and helps slow down its stretching.
• ARBs (Angiotensin Receptor Blockers) (e.g., losartan): These medicines lower blood pressure and may also block some of the abnormal signaling that causes the aorta to weaken. They are an alternative to beta-blockers or can be used in combination.

These medicines must be taken every day for life.

Regular Check-Ups:

• Yearly echocardiograms (heart ultrasounds) to measure the aorta.
• Yearly eye exams to check for lens problems or retinal issues.
• Monitoring for scoliosis (spine curve) during childhood and adolescence.

Surgery (if needed):

• Aortic Root Surgery: If the aorta becomes too large (usually 5 cm or more in adults), surgery is done to replace the weak section with a strong tube (graft) before it can tear. This is a planned, life-saving operation.
• Eye Surgery: If the lens is severely dislocated and causing vision problems.
• Spine or Chest Surgery: For severe scoliosis or pectus deformity.

Lifestyle Changes:

• Avoid contact sports (like rugby, football, boxing) because a blow to the chest could damage the aorta or eyes.
• Avoid heavy weightlifting and intense exercise that causes sudden spikes in blood pressure.
• Safe activities: Swimming, cycling, walking, and light jogging are encouraged.

Can People with Marfan Syndrome Live Normal Lives?

Yes! With proper treatment and monitoring, people with Marfan Syndrome can live long, healthy, and active lives. Life expectancy used to be only about 30-40 years before modern treatments, but now, with medications, regular check-ups, and surgery when needed, people with Marfan can live nearly as long as people without the condition.

Many people with Marfan Syndrome go to university, have careers, get married, and have children. The key is to:

• Take medicines as prescribed
• Go to regular check-ups
• Avoid risky activities
• Have surgery if and when the doctor recommends it

Can Women with Marfan Syndrome Have Children?

Yes, but pregnancy needs to be carefully planned and monitored. Pregnancy increases the stress on the heart and aorta because blood volume increases. The risk of aortic dissection is higher during pregnancy, especially in the last three months and the first month after delivery.

Before getting pregnant, a woman with Marfan Syndrome should have an echocardiogram to check the size of her aorta:

• If the aorta is less than 4 cm, pregnancy is usually safe (with close monitoring).
• If the aorta is 4-4.5 cm, pregnancy is moderate risk and requires very close monitoring (monthly heart ultrasounds).
• If the aorta is more than 4.5 cm, pregnancy is high risk and may be advised against. Surgery to repair the aorta before pregnancy may be recommended.

During pregnancy, women continue taking beta-blockers (which are safe) and have monthly echocardiograms. Delivery is usually planned with a specialized team, and sometimes a cesarean section is recommended to avoid the strain of pushing.

What About My Children?

If you have Marfan Syndrome, each of your children has a 50% chance of inheriting it. Children can be tested:

• Genetic testing: If your specific FBN1 mutation is known, your child can be tested with a blood test at any age, even as a baby.
• Clinical evaluation: Even if genetic testing is not done, children should have regular check-ups with a cardiologist (heart ultrasound) and ophthalmologist (eye exam) to monitor for signs of Marfan.

Early diagnosis in children is important so that treatment can start early to protect the heart.

Where Can I Find Support?

There are support groups and organizations for people with Marfan Syndrome and their families:

• National Marfan Foundation (USA): www.marfan.org
• Marfan Trust (UK): www.marfantrust.org
• Marfan Foundation Australia: www.marfan.org.au

These organizations provide information, connect families, and advocate for people with Marfan Syndrome.

Key Takeaway

Marfan Syndrome is a serious condition, but with modern medicine, it is very manageable. The most important things are:

1. Take your medicines every day.
2. Go to your check-ups (heart ultrasound, eye exam).
3. Know the warning signs of aortic dissection (sudden, severe chest or back pain) and get emergency help if this happens.
4. Live an active but safe life (avoid contact sports and heavy lifting).

With these steps, people with Marfan Syndrome can lead full, active, and long lives.

---

12. References

Primary Sources

1. Dietz HC, Cutting GR, Pyeritz RE, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature. 1991;352(6333):337-339. doi:10.1038/352337a0

2. Keane MG, Pyeritz RE. Medical management of Marfan syndrome. Circulation. 2008;117(21):2802-2813. doi:10.1161/CIRCULATIONAHA.107.693523

3. Silverman DI, Burton KJ, Gray J, et al. Life expectancy in the Marfan syndrome. Am J Cardiol. 1995;75(2):157-160. doi:10.1016/s0002-9149(00)80066-1

4. Groenink M, den Hartog AW, Franken R, et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur Heart J. 2013;34(45):3491-3500. doi:10.1093/eurheartj/eht334

5. Loeys BL, Dietz HC, Braverman AC, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet. 2010;47(7):476-485. doi:10.1136/jmg.2009.072785

6. Von Kodolitsch Y, De Backer J, Schüler H, et al. Perspectives on the revised Ghent criteria for the diagnosis of Marfan syndrome. Appl Clin Genet. 2015;8:137-155. doi:10.2147/TACG.S60472

7. Walker BA, Murdoch JL. The wrist sign: a useful physical finding in the Marfan syndrome. Arch Intern Med. 1970;126(2):276-277.

8. Pyeritz RE, McKusick VA. The Marfan syndrome: diagnosis and management. N Engl J Med. 1979;300(14):772-777. doi:10.1056/NEJM197904053001406

9. Gautier M, Detaint D, Fermanian C, et al. Nomograms for aortic root diameters in children using two-dimensional echocardiography. Am J Cardiol. 2010;105(6):888-894. doi:10.1016/j.amjcard.2009.11.040

10. Campens L, Demulier L, De Groote K, et al. Reference values for echocardiographic assessment of the diameter of the aortic root and ascending aorta spanning all age categories. Am J Cardiol. 2014;114(6):914-920. doi:10.1016/j.amjcard.2014.06.024

11. Neptune ER, Frischmeyer PA, Arking DE, et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet. 2003;33(3):407-411. doi:10.1038/ng1116

12. Loeys BL, Chen J, Neptune ER, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet. 2005;37(3):275-281. doi:10.1038/ng1511

13. Judge DP, Dietz HC. Marfan's syndrome. Lancet. 2005;366(9501):1965-1976. doi:10.1016/S0140-6736(05)67789-6

14. Faivre L, Collod-Beroud G, Loeys BL, et al. Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study. Am J Hum Genet. 2007;81(3):454-466. doi:10.1086/520125

15. Pepin M, Schwarze U, Superti-Furga A, Byers PH. Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. N Engl J Med. 2000;342(10):673-680. doi:10.1056/NEJM200003093421001

16. Robinson PN, Godfrey M. The molecular genetics of Marfan syndrome and related microfibrillopathies. J Med Genet. 2000;37(1):9-25. doi:10.1136/jmg.37.1.9

17. Pyeritz RE. Marfan syndrome: improved clinical history results in expanded natural history. Genet Med. 2019;21(8):1683-1690. doi:10.1038/s41436-018-0399-4

18. Morse RP, Rockenmacher S, Pyeritz RE, et al. Diagnosis and management of infantile Marfan syndrome. Pediatrics. 1990;86(6):888-895.

19. Stheneur C, Collod-Beroud G, Faivre L, et al. Identification of the minimal combination of clinical features in probands for efficient mutation detection in the FBN1 gene. Eur J Hum Genet. 2009;17(9):1121-1128. doi:10.1038/ejhg.2009.36

20. Meijboom LJ, Drenthen W, Pieper PG, et al. Obstetric complications in Marfan syndrome. Int J Cardiol. 2006;110(1):53-59. doi:10.1016/j.ijcard.2005.07.017

21. Donnelly RT, Pinto NM, Kocolas I, Yetman AT. The immediate and long-term impact of pregnancy on aortic growth rate and mortality in women with Marfan syndrome. J Am Coll Cardiol. 2012;60(3):224-229. doi:10.1016/j.jacc.2012.03.051

22. Collod-Beroud G, Le Bourdelles S, Ades L, et al. Update of the UMD-FBN1 mutation database and creation of an FBN1 polymorphism database. Hum Mutat. 2003;22(3):199-208. doi:10.1002/humu.10249

23. Milewicz DM, Dietz HC, Miller DC. Treatment of aortic disease in patients with Marfan syndrome. Circulation. 2005;111(11):e150-e157. doi:10.1161/01.CIR.0000155243.70456.F4

24. Ramirez F, Sakai LY. Biogenesis and function of fibrillin assemblies. Cell Tissue Res. 2010;339(1):71-82. doi:10.1007/s00441-009-0822-x

25. Jeremy RW, Huang H, Hwa J, et al. Relation between age, arterial distensibility, and aortic dilatation in the Marfan syndrome. Am J Cardiol. 1994;74(4):369-373. doi:10.1016/0002-9149(94)90405-7

26. Matt P, Schoenhoff F, Habashi J, et al. Circulating transforming growth factor-beta in Marfan syndrome. Circulation. 2009;120(6):526-532. doi:10.1161/CIRCULATIONAHA.108.841981

27. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006;312(5770):117-121. doi:10.1126/science.1124287

28. Holm TM, Habashi JP, Doyle JJ, et al. Noncanonical TGFbeta signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science. 2011;332(6027):358-361. doi:10.1126/science.1192149

29. Jondeau G, Detaint D, Tubach F, et al. Aortic event rate in the Marfan population: a cohort study. Circulation. 2012;125(2):226-232. doi:10.1161/CIRCULATIONAHA.111.054676

30. Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease. Circulation. 2010;121(13):e266-e369. doi:10.1161/CIR.0b013e3181d4739e

31. Freed LA, Levy D, Levine RA, et al. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med. 1999;341(1):1-7. doi:10.1056/NEJM199907013410101

32. Sponseller PD, Hobbs W, Riley LH 3rd, Pyeritz RE. The thoracolumbar spine in Marfan syndrome. J Bone Joint Surg Am. 1995;77(6):867-876. doi:10.2106/00004623-199506000-00007

33. Hakim AJ, Grahame R. A simple questionnaire to detect hypermobility: an adjunct to the assessment of patients with diffuse musculoskeletal pain. Int J Clin Pract. 2003;57(3):163-166.

34. Maumenee IH. The eye in the Marfan syndrome. Trans Am Ophthalmol Soc. 1981;79:684-733.

35. Pyeritz RE. Pulmonary and inguinal manifestations of heritable disorders of connective tissue. Clin Chest Med. 1980;1(2):221-234.

36. Fattori R, Nienaber CA, Descending Thoracic Aortic Diameter of 5.5 cm or Greater Is Not an Accurate Predictor of Acute Type B Aortic Dissection. Circulation. 2007;115(20):2613-2614; author reply 2614. doi:10.1161/CIRCULATIONAHA.106.682591

37. Loeys BL, Dietz HC, Braverman AC, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet. 2010;47(7):476-485. doi:10.1136/jmg.2009.072785

38. MacCarrick G, Black JH 3rd, Bowdin S, et al. Loeys-Dietz syndrome: a primer for diagnosis and management. Genet Med. 2014;16(8):576-587. doi:10.1038/gim.2014.11

39. Beighton P, De Paepe A, Steinmann B, Tsipouras P, Wenstrup RJ. Ehlers-Danlos syndromes: revised nosology, Villefranche, 1997. Am J Med Genet. 1998;77(1):31-37.

40. Peters KF, Kong F, Hanslo M, Biesecker BB. Living with Marfan syndrome III. Quality of life and reproductive planning. Clin Genet. 2002;62(2):110-120. doi:10.1034/j.1399-0004.2002.620203.x

41. Yetman AT, Bornemeier RA, McCrindle BW. Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome. Am J Cardiol. 2005;95(9):1125-1127. doi:10.1016/j.amjcard.2005.01.032

42. Merk DR, Chin JT, Dake BA, et al. miR-29b participates in early aneurysm development in Marfan syndrome. Circ Res. 2012;110(2):312-324. doi:10.1161/CIRCRESAHA.111.253740

43. Radke RM, Baumgartner H. Diagnosis and treatment of Marfan syndrome: an update. Heart. 2014;100(17):1382-1391. doi:10.1136/heartjnl-2013-304709

44. Gersony DR, McClaughlin MA, Jin Z, Gersony WM. The effect of beta-blocker therapy on clinical outcome in patients with Marfan's syndrome: a meta-analysis. Int J Cardiol. 2007;114(3):303-308. doi:10.1016/j.ijcard.2005.11.116

45. Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N Engl J Med. 1994;330(19):1335-1341. doi:10.1056/NEJM199405123301902

46. Lacro RV, Dietz HC, Sleeper LA, et al. Atenolol versus losartan in children and young adults with Marfan's syndrome. N Engl J Med. 2014;371(22):2061-2071. doi:10.1056/NEJMoa1404731

47. Mullen M, Jin XY, Child A, et al. Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial. Lancet. 2019;394(10216):2263-2270. doi:10.1016/S0140-6736(19)32518-8

48. Forteza A, Evangelista A, Sanchez V, et al. Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial. Eur Heart J. 2016;37(12):978-985. doi:10.1093/eurheartj/ehv575

49. Svensson LG, Crawford ES, Coselli JS, Safi HJ, Hess KR. Impact of cardiovascular operation on survival in the Marfan patient. Circulation. 1989;80(3 Pt 1):I233-I242.

50. David TE, Feindel CM, David CM, Manlhiot C. A quarter of a century of experience with aortic valve-sparing operations. J Thorac Cardiovasc Surg. 2014;148(3):872-879; discussion 879-880. doi:10.1016/j.jtcvs.2014.04.048

51. Gott VL, Greene PS, Alejo DE, et al. Replacement of the aortic root in patients with Marfan's syndrome. N Engl J Med. 1999;340(17):1307-1313. doi:10.1056/NEJM199904293401702

52. Gillinov AM, Cosgrove DM, Blackstone EH, et al. Durability of mitral valve repair for degenerative disease. J Thorac Cardiovasc Surg. 1998;116(5):734-743. doi:10.1016/S0022-5223(98)00450-4

53. Sponseller PD, Ahn NU, Ahn UM, et al. Osseous anatomy of the lumbosacral spine in Marfan syndrome. Spine (Phila Pa 1976). 2000;25(21):2797-2802. doi:10.1097/00007632-200011010-00014

54. Braverman AC. Exercise and the Marfan syndrome. Med Sci Sports Exerc. 1998;30(10 Suppl):S387-S395. doi:10.1097/00005768-199810001-00008

55. Peters KF, Kong F, Horne K, Francomano CA, Biesecker BB. Living with Marfan syndrome I. Perceptions of the condition. Clin Genet. 2001;60(4):273-282. doi:10.1034/j.1399-0004.2001.600406.x

56. Hagan PG, Nienaber CA, Isselbacher EM, et al. The International Registry of Acute Aortic Dissection (IRAD): new insights into an old disease. JAMA. 2000;283(7):897-903. doi:10.1001/jama.283.7.897

57. Verghese C. Anaesthesia in Marfan's syndrome. Anaesthesia. 1984;39(9):917-922. doi:10.1111/j.1365-2044.1984.tb06587.x

58. Stuart AG, Williams A. Marfan's syndrome and the heart. Arch Dis Child. 2007;92(4):351-356. doi:10.1136/adc.2006.105577

59. Erbel R, Aboyans V, Boileau C, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases. Eur Heart J. 2014;35(41):2873-2926. doi:10.1093/eurheartj/ehu281

60. Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease. J Am Coll Cardiol. 2010;55(14):e27-e129. doi:10.1016/j.jacc.2010.02.015

61. Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J. 2021;42(6):563-645. doi:10.1093/eurheartj/ehaa554

62. Khairy P, Van Hare GF, Balaji S, et al. PACES/HRS expert consensus statement on the recognition and management of arrhythmias in adult congenital heart disease. Heart Rhythm. 2014;11(10):e102-e165. doi:10.1016/j.hrthm.2014.05.009

63. Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N Engl J Med. 1994;330(19):1335-1341. doi:10.1056/NEJM199405123301902

64. Gott VL, Greene PS, Alejo DE, et al. Replacement of the aortic root in patients with Marfan's syndrome. N Engl J Med. 1999;340(17):1307-1313. doi:10.1056/NEJM199904293401702

65. Meijboom LJ, Timmermans J, Zwinderman AH, Engelfriet PM, Mulder BJ. Aortic root growth in men and women with the Marfan's syndrome. Am J Cardiol. 2005;96(10):1441-1444. doi:10.1016/j.amjcard.2005.06.094

66. Treasure T, Takkenberg JJM, Golesworthy T, et al. Personalised external aortic root support (PEARS) in Marfan syndrome: analysis of 1-9 year outcomes by intention-to-treat in a cohort study of 216 patients. Br J Surg. 2017;104(9):1168-1176. doi:10.1002/bjs.10566

---

13. Examination Focus

High-Yield MRCPCH / Paediatric Cardiology Exam Topics

Short Cases / OSCE Stations:

1. "Examine this child's cardiovascular system":

   • Inspection: Tall, thin, long limbs (dolichostenomelia), pectus deformity, arachnodactyly
   • Palpation: Hyperdynamic apex (if AR/MR), thrill (if severe MR)
   • Auscultation:
     • Mid-systolic click + late systolic murmur (MVP)
     • Early diastolic murmur (AR, left sternal border, patient sitting forward)
   • Complete Exam: Peripheral pulses (assess for dissection/AR), blood pressure both arms (dissection), radial-femoral delay (coarctation differential)
   • Additional Features: Check wrist/thumb signs, examine spine (scoliosis), high-arched palate

2. "This 14-year-old presents with chest pain. Examine and discuss":

   • Key Differential: Marfan → Aortic Dissection vs Pneumothorax vs Musculoskeletal
   • Red Flags: Severe tearing pain, syncope, pulse deficit → AORTIC DISSECTION (emergency)
   • Investigations: ECG (ST changes if dissection involves coronary ostia), CXR (widened mediastinum, pneumothorax), urgent CT Angiography
   • Management: If dissection → IV beta-blocker (labetalol), analgesia, urgent cardiothoracic surgery

Data Interpretation Stations:

1. Echocardiogram Report:

   • Aortic root diameter 38mm, Z-score +3.2
   • Mild mitral regurgitation, MVP present
   • Interpretation: Significant aortic dilatation (Z> 3), meets Ghent criterion
   • Management: Start beta-blocker, 6-monthly echo, genetics referral

2. Genetic Report:

   • "Heterozygous pathogenic variant in FBN1 gene (c.1234C>T, p.Arg412Cys)"
   • Interpretation: Confirms Marfan syndrome diagnosis
   • Family Implications: 50% risk to offspring, cascade screening for siblings/parents

Viva Topics:

1. "Tell me about the pathophysiology of Marfan syndrome":

   • Expected Answer: Dual mechanism:
     • Structural: FBN1 mutation → defective fibrillin-1 → weak microfibrils → reduced elasticity (aorta, ligaments, zonules)
     • Signaling: Defective fibrillin cannot sequester TGF-beta → excessive TGF-beta signaling → smooth muscle apoptosis, MMP activation, bone overgrowth
   • High-Yield Point: TGF-beta hypothesis explains why ARBs (losartan) may be beneficial

2. "Revised Ghent Nosology - how do you diagnose Marfan?":

   • Without Family History: Need Aortic Root (Z≥2) + ONE of:
     • Ectopia Lentis OR
     • FBN1 mutation OR
     • Systemic Score ≥7
   • With Family History: Need ONE of:
     • Ectopia Lentis OR
     • Systemic Score ≥7 OR
     • Aortic Root (Z≥2 if > 20 years, Z≥3 if less than 20 years)

3. "Indications for aortic root surgery in Marfan?":

   • Adult: ≥50mm
   • Family History of Dissection: ≥45mm
   • Rapid Growth: > 3-5mm/year or > 0.5 Z-score/year
   • Severe AR: Adding to ventricular dysfunction
   • Pregnancy Planning: If 40-45mm, consider prophylactic surgery before conception

4. "Atenolol vs Losartan - what does the evidence say?":

   • Lacro Trial (NEJM 2014): RCT in children, NO significant difference in aortic root Z-score change
   • Conclusion: Both effective; beta-blockers remain first-line (stronger historical evidence), losartan equivalent alternative
   • Combination: COMPARE trial showed NO added benefit of losartan + beta-blocker vs beta-blocker alone

Common MCQ/SBA Themes:

1. Genetics:

   • Inheritance: Autosomal Dominant
   • De novo rate: 25%
   • Gene: FBN1 (chromosome 15)

2. Differentials:

   • Homocystinuria: Intellectual disability, thrombosis, DOWNWARD lens dislocation, elevated urinary homocysteine
   • Loeys-Dietz: Hypertelorism, bifid uvula, arterial tortuosity, aggressive aortic disease (TGFBR1/2)
   • Ehlers-Danlos (vascular): Thin skin, easy bruising, arterial rupture (COL3A1)

3. Complications:

   • Most common cause of death: Aortic dissection (Type A)
   • Ocular emergency: Retinal detachment
   • Pulmonary: Spontaneous pneumothorax

4. Management:

   • First-line medical: Beta-blockers (reduce dP/dt)
   • Surgical threshold: 50mm (45mm if family history dissection)
   • Pregnancy: High risk if aortic root > 45mm

Mnemonics and Memory Aids

"MARFAN" for Systemic Features:

• Mitral valve prolapse
• Aortic root dilatation
• Reduced Upper:Lower segment ratio
• Flat feet (Pes planus)
• Arachnodactyly (Thumb/Wrist signs)
• Near-sighted (Myopia), eNophthalmos

"LENS UP" for Ectopia Lentis Direction:

• LENS goes UP (and out = superotemporal) in Marfan
• (vs DOWN in Homocystinuria)

"2-3-5 Rule" for Aortic Surgery:

• Z-score ≥2 = Dilatation (meets Ghent)
• Z-score ≥3 = Severe (6-monthly echo)
• Diameter ≥5 cm = Surgery (adult)

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference only. Clinical decisions must account for individual patient circumstances, local guidelines, and consultation with appropriate specialists. This content does not replace professional medical judgment.